Evidence map›Paper›PMID 33172393›Full record

ArticleBMC infectious diseases2020

Short- and long-term humoral immune response against Yersinia pestis in plague patients, Madagascar.

Voahangy Andrianaivoarimanana, Alice Lantoniaina Iharisoa, Lila Rahalison, Marie Laurette Ralimanantsoa, Maherisoa Ratsitorahina, Rado J L Rakotonanahary, Elisabeth Carniel, Christian Demeure, Minoarisoa Rajerison

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Transmission of Antimicrobial Resistant Yersinia pestis During a Pneumonic Plague Outbreak.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Voahangy AndrianaivoarimananaPlague Unit, Institut Pasteur de Madagascar, 101, Antananarivo, Madagascar. kekely@pasteur.mg.ORCID http://orcid.org/0000-0003-1550-3869
Alice Lantoniaina IharisoaPlague Unit, Institut Pasteur de Madagascar, 101, Antananarivo, Madagascar.
Lila RahalisonPlague Unit, Institut Pasteur de Madagascar, 101, Antananarivo, Madagascar.
Marie Laurette RalimanantsoaCentral Laboratory for Plague, Ministry of Public Health, 101, Antananarivo, Madagascar.
Maherisoa RatsitorahinaEpidemiology Unit, Institut Pasteur de Madagascar, 101, Antananarivo, Madagascar.
Rado J L RakotonanaharyPlague Unit, Institut Pasteur de Madagascar, 101, Antananarivo, Madagascar.
Elisabeth CarnielYersinia Research Unit, Institut Pasteur, 75724, Paris, France.
Christian DemeureYersinia Research Unit, Institut Pasteur, 75724, Paris, France.
Minoarisoa RajerisonPlague Unit, Institut Pasteur de Madagascar, 101, Antananarivo, Madagascar.
Institut Pasteur de Madagascar · MGInstitut Pasteur · FRMinistry of Public Health · MGUniversity of Antananarivo · MG

Funding

Institut Pasteur Grant ACIM- 5- 3 and ACIP A- 21- 2012
6 · The paper itself

Abstract

backgroundPlague, a fatal disease caused by the bacillus, Yersinia pestis, still affects resources-limited countries. Information on antibody response to plague infection in human is scarce. Anti-F1 Ig G are among the known protective antibodies against Y. pestis infection. As a vaccine preventable disease, knowledge on antibody response is valuable for the development of an effective vaccine to reduce infection rate among exposed population in plague-endemic regions. In this study, we aim to describe short and long-term humoral immune responses against Y. pestis in plague-confirmed patients from Madagascar, the most affected country in the world.

methodsBubonic (BP) and pneumonic plague (PP) patients were recruited from plague- endemic foci in the central highlands of Madagascar between 2005 and 2017. For short-term follow-up, 6 suspected patients were enrolled and prospectively investigated for kinetics of the anti-F1 IgG response, whereas the persistence of antibodies was retrospectively studied in 71 confirmed convalescent patients, using an ELISA which was validated for the detection of plague in human blood samples in Madagascar.

resultsSimilarly to previous findings, anti-F1 IgG rose quickly during the first week after disease onset and increased up to day 30. In the long-term study, 56% of confirmed cases remained seropositive, amongst which 60 and 40% could be considered as high- and low-antibody responders, respectively. Antibodies persisted for several years and up to 14.8 years for one individual. Antibody titers decreased over time but there was no correlation between titer and time elapsed between the disease onset and serum sampling. In addition, the seroprevalence rate was not significantly different between gender (P = 0.65) nor age (P = 0.096).

conclusionOur study highlighted that the circulating antibody response to F1 antigen, which is specific to Y. pestis, may be attributable to individual immune responsiveness. The finding that a circulating anti-F1 antibody titer could persist for more than a decade in both BP and PP recovered patients, suggests its probable involvement in patients' protection. However, complementary studies including analyses of the cellular immune response to Y. pestis are required for the better understanding of long-lasting protection and development of a potential vaccine against plague.

Indexed as

Immunity, HumoralAdolescentAdultAnimalsAntibodies, BacterialAntigens, BacterialBacterial ProteinsChildFemaleFollow-Up StudiesHumansImmunoglobulin GMadagascarMalePlagueProspective StudiesAntibodies, BacterialAntigens, BacterialBacterial Proteinscaf1 protein, Yersinia pestisImmunoglobulin GHumanImmune responseMadagascarPlagueYersinia pestis

Identifiers

PMID33172393
PMCPMC7653777
OpenAlexW3099639876

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.